BioSpace News Archive

Sun Pharmaceutical Industries Inc., USA (Sun Pharma) today announced the publication of five-year Phase 3 efficacy and safety results for ILUMYA® (tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension studies in the British Journal of Dermatology.

University of Michigan Health Affiliate Halves Hypoglycemic Events and Reduces Hyperglycemia by 40% with Personalized Insulin Dosing Software

Savara Inc., an orphan lung disease company, announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share.

Alafair Biosciences, Inc., a commercial-stage medical device company, announced the launch of VersaWrap®, a bioresorbable hydrogel implant that provides a gelatinous, non-constricting interface between tendons and/or peripheral nerves and surrounding tissues.

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced that it will host a conference call to discuss the 2020 full year financial results and provide a corporate update at 9:00 a.m. Beijing time on March 29, 2021.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food & Drug Administration (FDA) has granted expanded access approval for the administration of Longeveron’s investigational cell therapy Lomecel-B to a child with Hypoplastic Left Heart Syndrome (HLHS).

Persephone Biosciences Inc., a privately held, data-driven microbiome-focused biotechnology company, today announced the initiation of the VOICES clinical study to determine the impact of gut microbiome composition and function on the immune system and efficacy of COVID-19 vaccination.

NAMSA®, the world’s only 100% medical device-focused Contract Research Organization providing full continuum development solutions, announced its executive leadership transition plan with the appointment of Dr. Christophe Berthoux as NAMSA’s new CEO, effective March 22, 2021.

The extraordinary general meeting in Medivir Aktiebolag on 11 March 2021 resolved, in accordance with the board of directors’ proposal, to raise approximately SEK 27,828,000 by a directed issue of not more than 3,600,000 new class B shares.

AFYX Therapeutics (“AFYX”), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that a study of the Rivelin® Clobetasol patch (“Rivelin-CLO”), a novel adhesive patch technology designed to deliver a therapeutic agent to wet tissue surfaces, was featured in the March issue of The European Journal of Oral Sciences.